<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Med</journal-id><journal-id journal-id-type="iso-abbrev">J Transl Med</journal-id><journal-title-group><journal-title>Journal of Translational Medicine</journal-title></journal-title-group><issn pub-type="epub">1479-5876</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4315269</article-id><article-id pub-id-type="publisher-id">1479-5876-13-S1-O5</article-id><article-id pub-id-type="doi">10.1186/1479-5876-13-S1-O5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Dummer</surname><given-names>Reinhard</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Daud</surname><given-names>Adil</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Puzanov</surname><given-names>Igor</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Hamid</surname><given-names>Omid</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Schadendorf</surname><given-names>Dirk</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Robert</surname><given-names>Caroline</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Schachter</surname><given-names>Jacob</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Pavlick</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Gonzalez</surname><given-names>Rene</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Hodi</surname><given-names>F Stephen</given-names></name><xref ref-type="aff" rid="I10">10</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Cranmer</surname><given-names>Lee D </given-names></name><xref ref-type="aff" rid="I11">11</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Blank</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="I12">12</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>O&#x02019;Day</surname><given-names>Steven J </given-names></name><xref ref-type="aff" rid="I13">13</xref></contrib><contrib contrib-type="author" id="A14"><name><surname>Ascierto</surname><given-names>Paolo A </given-names></name><xref ref-type="aff" rid="I14">14</xref></contrib><contrib contrib-type="author" id="A15"><name><surname>Salama</surname><given-names>April K S </given-names></name><xref ref-type="aff" rid="I15">15</xref></contrib><contrib contrib-type="author" id="A16"><name><surname>Li</surname><given-names>Nicole Xiaoyun</given-names></name><xref ref-type="aff" rid="I16">16</xref></contrib><contrib contrib-type="author" id="A17"><name><surname>Zhou</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="I16">16</xref></contrib><contrib contrib-type="author" id="A18"><name><surname>Lis</surname><given-names>Joy</given-names></name><xref ref-type="aff" rid="I16">16</xref></contrib><contrib contrib-type="author" id="A19"><name><surname>Ebbinghaus</surname><given-names>Scot</given-names></name><xref ref-type="aff" rid="I16">16</xref></contrib><contrib contrib-type="author" id="A20"><name><surname>Kang</surname><given-names>Peter S </given-names></name><xref ref-type="aff" rid="I16">16</xref></contrib><contrib contrib-type="author" id="A21"><name><surname>Ribas</surname><given-names>Antoni</given-names></name><xref ref-type="aff" rid="I17">17</xref></contrib></contrib-group><aff id="I1"><label>1</label>Department of Dermatology, University of Zurich, Zurich, Switzerland</aff><aff id="I2"><label>2</label>Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA, USA</aff><aff id="I3"><label>3</label>Division of Hematology-Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA</aff><aff id="I4"><label>4</label>Melanoma Center, The Angeles Clinic and Research Institute, Los Angeles, CA, USA</aff><aff id="I5"><label>5</label>Department of Dermatology, University Hospital Essen, Essen, Germany</aff><aff id="I6"><label>6</label>Dermatology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif, France</aff><aff id="I7"><label>7</label>Oncology Division, Sheba Medical Center, Tel Hashomer, Israel</aff><aff id="I8"><label>8</label>Department of Medicine, New York University Perlmutter Cancer Center, New York, NY, USA</aff><aff id="I9"><label>9</label>Division of Medical Oncology, University of Colorado Denver, Denver, CO, USA</aff><aff id="I10"><label>10</label>Melanoma Center, Dana-Farber Cancer Institute, Boston, MA, USA</aff><aff id="I11"><label>11</label>Department of Hematology/Oncology, University of Arizona Cancer Center, Tucson, AZ, USA</aff><aff id="I12"><label>12</label>Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands</aff><aff id="I13"><label>13</label>Department of Medical Oncology, Beverly Hills Cancer Center, Beverly Hills, CA, USA</aff><aff id="I14"><label>14</label>Unit of Medical Oncology and Innovative Therapy, National Tumor Institute Fondazione &#x0201c;G. Pascale,&#x0201d; Naples, Italy</aff><aff id="I15"><label>15</label>Department of Medicine, Duke Cancer Institute, Durham, NC, USA</aff><aff id="I16"><label>16</label>Merck &#x00026; Co., Inc., Whitehouse Station, NJ, USA</aff><aff id="I17"><label>17</label>Jonnson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA, USA</aff><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>15</day><month>1</month><year>2015</year></pub-date><volume>13</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Melanoma Bridge 2014: meeting abstracts</named-content><named-content content-type="supplement-editor">Paolo A Ascierto, Gennaro Ciliberto, John M Kirkwood, Francesco M Marincola, Giuseppe Masucci, Ignacio Melero, Nicola Mozzillo, Giuseppe Palmieri and Magdalena Thurin.</named-content><named-content content-type="supplement-sponsor">The publication charges for this supplement were funded by 3P solutions. Abstracts were evaluated by the Supplement Editors. Supplement Editor declarations: John Kirkwood reports grants from Prometheus and personal fees from BMS, Merck, GSK, Celgene, Vica and Ziopharm Oncology. Malero has received Consulting honoraria from Bristol Myers Squibb, Roche Genentech and Astra Zeneca. All other Supplement Editors declare that they have no competing interests.</named-content></supplement><fpage>O5</fpage><lpage>O5</lpage><permissions><copyright-statement>Copyright &#x000a9; 2015 Dummer et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Dummer et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.translational-medicine.com/content/13/S1/O5"/><conference><conf-date>3-6 December 2014</conf-date><conf-name>Melanoma Bridge Meeting 2014</conf-name><conf-loc>Naples, Italy</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>Pembrolizumab blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby inducing an antitumor immune response. In a phase I study, pembrolizumab demonstrated promising antitumor activity and acceptable safety in patients with ipilimumab-treated melanoma, leading to accelerated approval in the US.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>KEYNOTE-002 is a randomized phase 2 study in patients with ipilimumab-refractory melanoma (ie, confirmed PD in the 24 weeks following &#x02265;2 ipilimumab doses) and, if <italic>BRAF</italic> mutant, previously treated with a BRAF inhibitor. Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg Q3W or investigator-choice chemotherapy (carboplatin + paclitaxel, carboplatin, paclitaxel, dacarbazine, or temozolomide). Patients with PD confirmed by independent central review could cross over to pembrolizumab treatment after the first 3-month assessment. Primary objective of the interim analysis prespecified to occur after &#x02265; 270 PFS events (RECIST v1.1, independent central review) was to evaluate the superiority of either pembrolizumab dose over control for PFS at a 1-sided 0.25% significance level (estimated HR 0.66).</p></sec><sec sec-type="results"><title>Results</title><p>From Nov 2012 to Nov 2013, 540 patients from 12 countries enrolled. Based on central review of a total of 410 PFS events, the HR was 0.57 and 0.50 for pembrolizumab 2 and 10 mg/kg Q3W, respectively, over control (<italic>P</italic>&#x0003c;0.00001 for both comparisons). The 6-month PFS rate was 34% (95% CI 27%-41%) and 38% (95% CI 31%-45%) for pembrolizumab 2 and 10 mg/kg, respectively, compared with 16% (95% CI 10%-22%) for the control arm. PFS by investigator assessment was similar to that of central review. The PFS effect was consistent in all subgroups. ORR was 21% at 2 mg/kg, 25% at 10 mg/kg, and 4% in the control arm (<italic>P</italic>&#x0003c;0.0001 for both comparisons). Median response duration was not reached in either pembrolizumab arm and was 37 weeks in the control arm. Forty-eight percent of patients in the control arm crossed over to pembrolizumab treatment. OS data are not mature (final OS analysis will be performed after 370 deaths have occurred). The safety profile was consistent with that previously observed for pembrolizumab. Despite a decreased therapy duration, rates of grade 3-5 drug-related AEs were numerically higher in the chemotherapy control arm (26%) than in the pembrolizumab 2-mg/kg (11%) and 10-mg/kg (14%) arms.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Both pembrolizumab doses met prespecified criteria for PFS superiority over the chemotherapy control arm. Pembrolizumab significantly prolongs PFS compared with chemotherapy, approximately doubling the 6-month rate in an ipilimumab-refractory population.</p></sec><sec><title>Clinical trial registration number</title><p>NCT01704287</p></sec></body></article>